Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Gaucher disease: haematological presentations and complications.

Thomas AS, Mehta A, Hughes DA.

Br J Haematol. 2014 May;165(4):427-40. doi: 10.1111/bjh.12804. Review.

PMID:
24588457
2.

[Gaucher's disease ].

Belmatoug N, Caubel I, Stirnemann J, Billette de Villemeur T.

J Soc Biol. 2002;196(2):141-9. Review. French.

PMID:
12360743
3.

Gaucher Disease: Clinical, Biological and Therapeutic Aspects.

Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S.

Pathobiology. 2016;83(1):13-23. doi: 10.1159/000440865. Review.

4.

Gaucher disease.

Guggenbuhl P, Grosbois B, Chalès G.

Joint Bone Spine. 2008 Mar;75(2):116-24. Review.

PMID:
17996473
5.

The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Hughes DA, Pastores GM.

Wien Med Wochenschr. 2010 Dec;160(23-24):594-9. doi: 10.1007/s10354-010-0864-4. Review.

PMID:
21221911
6.

[Gaucher's disease: pathogenesis, diagnosis and therapy].

Pregun I, Tulassay Z.

Orv Hetil. 2004 Sep 12;145(37):1883-90. Review. Hungarian.

PMID:
15493618
7.

Gaucher disease: unmet treatment needs.

Mehta A.

Acta Paediatr. 2008 Apr;97(457):83-7. doi: 10.1111/j.1651-2227.2008.00653.x. Review.

PMID:
18339195
8.

The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Velayati A, Yu WH, Sidransky E.

Curr Neurol Neurosci Rep. 2010 May;10(3):190-8. doi: 10.1007/s11910-010-0102-x. Review.

9.

Gaucher disease: a lysosomal neurodegenerative disorder.

Huang WJ, Zhang X, Chen WW.

Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1219-26. Review.

10.

[Gaucher disease: clinical, genetic and therapeutic aspects].

Germain DP.

Pathol Biol (Paris). 2004 Jul;52(6):343-50. Review. French.

PMID:
15261378
11.
12.

[Hematological aspects of Gaucher disease].

Costello R, O'Callaghan T, Baccini V, Sébahoun G.

Rev Med Interne. 2007 Oct;28 Suppl 2:S176-9. Review. French.

PMID:
18228684
13.

The role of neurogenetics in Gaucher disease.

Brady RO, Barton NW, Grabowski GA.

Arch Neurol. 1993 Nov;50(11):1212-24. Review.

PMID:
8215980
14.

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.

Yang NY, Lee YN, Lee HJ, Kim YS, Lee SJ.

Biol Chem. 2013 Jul;394(7):807-18. doi: 10.1515/hsz-2012-0322. Review.

PMID:
23435096
15.

Substrate reduction therapy of glycosphingolipid storage disorders.

Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M.

J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):449-56.

PMID:
16763917
16.

[Clinical characteristics of the neurological forms of Gaucher's disease].

Capablo Liesa JL, de Cabezón AS, Alarcia Alejos R, Ara Callizo JR.

Med Clin (Barc). 2011 Sep;137 Suppl 1:6-11. doi: 10.1016/S0025-7753(11)70010-0. Spanish.

PMID:
22230119
17.

Gaucher disease: multiple lessons from a single gene disorder.

Beutler E.

Acta Paediatr Suppl. 2006 Apr;95(451):103-9. Review.

PMID:
16720474
18.

Miscellaneous non-inflammatory musculoskeletal conditions. Gaucher disease and bone.

Mikosch P.

Best Pract Res Clin Rheumatol. 2011 Oct;25(5):665-81. doi: 10.1016/j.berh.2011.10.015. Review.

PMID:
22142746
19.

Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.

van Dussen L, Biegstraaten M, Dijkgraaf MG, Hollak CE.

Orphanet J Rare Dis. 2014 Jul 24;9:112. doi: 10.1186/s13023-014-0112-x.

20.

Gaucher disease: review of the literature.

Chen M, Wang J.

Arch Pathol Lab Med. 2008 May;132(5):851-3. doi: 10.1043/1543-2165(2008)132[851:GDROTL]2.0.CO;2. Review.

PMID:
18466035
Items per page

Supplemental Content

Support Center